Citadel Advisors’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $897K | Buy |
46,800
+18,400
| +65% | +$400K | ﹤0.01% | 7913 |
|
|
2025
Q4 | $624K | Sell |
28,400
-16,600
| -37% | -$300K | ﹤0.01% | 8487 |
|
|
2025
Q3 | $546K | Buy |
45,000
+16,800
| +60% | +$227K | ﹤0.01% | 8915 |
|
|
2025
Q2 | $526K | Buy |
28,200
+6,200
| +28% | +$123K | ﹤0.01% | 8512 |
|
|
2025
Q1 | $422K | Sell |
22,000
-29,900
| -58% | -$875K | ﹤0.01% | 8857 |
|
|
2024
Q4 | $1.87M | Sell |
51,900
-25,300
| -33% | -$856K | ﹤0.01% | 5770 |
|
|
2024
Q3 | $3.27M | Sell |
77,200
-23,900
| -24% | -$1.01M | ﹤0.01% | 4641 |
|
|
2024
Q2 | $4.07M | Buy |
101,100
+12,700
| +14% | +$530K | ﹤0.01% | 4069 |
|
|
2024
Q1 | $3.13M | Buy |
88,400
+35,200
| +66% | +$943K | ﹤0.01% | 4705 |
|
|
2023
Q4 | $1.57M | Buy |
53,200
+4,000
| +8% | +$83K | ﹤0.01% | 5804 |
|
|
2023
Q3 | $1.02M | Buy |
49,200
+17,000
| +53% | +$467K | ﹤0.01% | 6515 |
|
|
2023
Q2 | $790K | Sell |
32,200
-16,900
| -34% | -$544K | ﹤0.01% | 6949 |
|
|
2023
Q1 | $1.99M | Sell |
49,100
-105,300
| -68% | -$4.36M | ﹤0.01% | 5374 |
|
|
2022
Q4 | $6.94M | Buy |
154,400
+37,200
| +32% | +$1.68M | ﹤0.01% | 3338 |
|
|
2022
Q3 | $5.61M | Sell |
117,200
-17,400
| -13% | -$954K | ﹤0.01% | 3683 |
|
|
2022
Q2 | $7.97M | Buy |
134,600
+29,200
| +28% | +$2.4M | ﹤0.01% | 2980 |
|
|
2022
Q1 | $12.3M | Sell |
105,400
-69,400
| -40% | -$8.1M | ﹤0.01% | 2649 |
|
|
2021
Q4 | $26.3M | Buy |
174,800
+20,000
| +13% | +$2.7M | 0.01% | 1729 |
|
|
2021
Q3 | $18.5M | Sell |
154,800
-10,000
| -6% | -$1.1M | ﹤0.01% | 2115 |
|
|
2021
Q2 | $16.1M | Sell |
164,800
-39,800
| -19% | -$3.55M | ﹤0.01% | 2367 |
|
|
2021
Q1 | $18.1M | Sell |
204,600
-52,500
| -20% | -$4.88M | ﹤0.01% | 2099 |
|
|
2020
Q4 | $24.6M | Buy |
257,100
+10,900
| +4% | +$1.12M | 0.01% | 1594 |
|
|
2020
Q3 | $27.9M | Buy |
246,200
+37,000
| +18% | +$3.89M | 0.01% | 1287 |
|
|
2020
Q2 | $20.7M | Buy |
209,200
+77,900
| +59% | +$6.22M | 0.01% | 1477 |
|
|
2020
Q1 | $8.45M | Sell |
131,300
-72,000
| -35% | -$5.04M | ﹤0.01% | 2057 |
|
|
2019
Q4 | $12.1M | Sell |
203,300
-69,900
| -26% | -$4.31M | 0.01% | 2005 |
|
|
2019
Q3 | $16.1M | Sell |
273,200
-4,900
| -2% | -$313K | 0.01% | 1690 |
|
|
2019
Q2 | $17.9M | Buy |
278,100
+46,100
| +20% | +$2.98M | 0.01% | 1523 |
|
|
2019
Q1 | $14.7M | Buy |
232,000
+45,900
| +25% | +$2.41M | 0.01% | 1625 |
|
|
2018
Q4 | $7.07M | Sell |
186,100
-52,300
| -22% | -$1.85M | ﹤0.01% | 2314 |
|
|
2018
Q3 | $10.2M | Buy |
238,400
+160,600
| +206% | +$5.61M | ﹤0.01% | 2069 |
|
|
2018
Q2 | $1.71M | Buy |
+77,800
| New | +$957K | ﹤0.01% | 4337 |
|
|
2017
Q3 | – | Sell |
-4,300
| Closed | -$34K | – | 8060 |
|
|
2017
Q2 | $34K | Buy |
+4,300
| New | +$39.7K | ﹤0.01% | 7179 |
|
Other funds holding TNDM
SC
VPM
ACH
VCM
GKIM
DCM
Citadel Advisors's TNDM Position: Q1 2026 in Review
Citadel Advisors increased its Tandem Diabetes Care (TNDM) stake by 5% in Q1 2026, buying an estimated $2.26M and bringing the position to 2,192,667 shares worth $42M. The position accounts for 0.01% of the portfolio, ranked #1524.
Citadel Advisors first reported a position in TNDM in Q2 2015 and has held it in 35 quarters since. The position peaked at $122M in Q4 2021. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.
- Citadel Advisors held 2,192,667 shares of Tandem Diabetes Care worth $42M as of Q1 2026.
- Citadel Advisors bought 104,064 Tandem Diabetes Care shares in Q1 2026, an estimated $2.26M.
- Tandem Diabetes Care made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1524 holding.
- Citadel Advisors first reported a position in Tandem Diabetes Care in Q2 2015 and has held it in 35 quarters since.
- Citadel Advisors's Tandem Diabetes Care position peaked at $122M in Q4 2021.
- 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.